A patient who says, “I’m having another panic attack,” after running out of alprazolam may be asking for relief—but the safest response is not simply refill versus refusal.
Consider a 29-year-old woman brought to the emergency department 36 hours after her last alprazolam dose. She had been prescribed 0.5 mg twice daily for panic symptoms four months earlier, but began taking extra doses before work and driving. During the past month, she used approximately 4–5 mg daily. Now she reports terror, palpitations, sweating, insomnia, tremulousness, facial tingling, marked sensitivity to light, and intermittent muscle jerks.
Her ECG shows sinus tachycardia. Glucose, electrolytes, thyroid testing, and cardiac biomarkers are unrevealing. She is frightened and repeatedly asks for enough alprazolam to “get through the week.”
The clinical stakes are easy to miss because panic and benzodiazepine withdrawal share autonomic symptoms. The discriminating question is whether the presentation is panic alone—or panic occurring inside a potentially dangerous withdrawal syndrome.
The key decision: what changed after the dose reduction?
Assume collateral history confirms that, before alprazolam was started, she had recurrent unexpected panic attacks followed by at least a month of persistent worry and avoidance. She stopped taking public transportation, missed work, and repeatedly sought medical reassurance. That baseline could support panic disorder if the attacks were not better explained by a substance, medical condition, or another mental disorder.
It does not explain everything happening now.
| Clinical feature | Panic attack more likely | Benzodiazepine withdrawal more concerning |
|---|---|---|
| Timing | Abrupt surge of fear that peaks over minutes and resembles prior attacks | Symptoms begin or intensify after missed, reduced, or delayed doses; may persist between attacks |
| Core symptoms | Palpitations, dyspnea, chest discomfort, sweating, trembling, paresthesias, fear of dying or losing control | New insomnia, marked tremor, sensory hypersensitivity, muscle twitching, severe agitation, perceptual changes, marked autonomic activation, or seizures |
| Interpretation | May occur as a primary anxiety syndrome | May coexist with panic and should prompt withdrawal-risk assessment; disposition depends on severity, co-occurring risks, and the ability to monitor safely |
The history of escalating doses is important, but it does not automatically prove benzodiazepine use disorder. It does establish tolerance as a possibility and raises concern that “the medication stopped working” may actually represent shorter duration of effect, interdose rebound, or emerging physical dependence.
Alprazolam is relatively short-acting. Early-morning anxiety or symptoms between doses can reflect tolerance or the interval outlasting the medication’s clinical effect. New neurologic or sensory symptoms after abrupt cessation should not be dismissed as a more dramatic version of the patient’s usual panic.
A patient can be both frightened by panic and physiologically withdrawing. These are not competing diagnoses.
Physical dependence is not the same as benzodiazepine use disorder
Regular benzodiazepine exposure can produce physical dependence even when the medication was prescribed and taken for a legitimate indication. Dependence means that abrupt reduction can cause withdrawal; it is not synonymous with addiction, diversion, or a substance use disorder.
A separate assessment should ask about loss of control, compulsive use, hazardous use, continued use despite harm, obtaining medication from multiple sources, and impairment in work or relationships. In this case, self-escalation and repeated early requests are clinically concerning, but the formulation should remain precise: she may have panic disorder complicated by alprazolam tolerance and physical dependence, with possible benzodiazepine use disorder requiring further assessment.
That distinction changes the clinician’s tone. The patient needs firm limits and a safer prescribing plan, not moral judgment. It also prevents the opposite error: using the label of dependence to justify abrupt discontinuation.
Management should follow withdrawal risk, not the refill demand
1. Stabilize and reassess medically
Repeat vital signs and mental-status examinations rather than relying on a single reassuring evaluation. Clarify the actual last dose, recent daily amount, missed doses, alcohol or opioid exposure, use of other sedatives, prior withdrawal symptoms, seizure history, pregnancy potential when relevant, and access to additional medications. Review prescription records and obtain collateral when the dose history is uncertain.
The initial workup should remain directed at dangerous alternatives, including arrhythmia, hypoglycemia, intoxication, infection, metabolic disturbance, medication toxicity, and other causes of altered mental status. A normal ECG or troponin may lower concern for an acute cardiac emergency in the vignette; it does not establish that the remaining symptoms are psychiatric.
2. Choose the level of care deliberately
A medically monitored setting should be considered when a patient has high-dose or escalating use, abrupt cessation of a short-acting benzodiazepine, substantial autonomic activation, severe insomnia, neurologic symptoms, unreliable follow-up, polysubstance exposure, or a significant medical or psychiatric comorbidity that may not be safely managed as an outpatient. These features lower the threshold for monitoring but do not, in isolation, determine disposition.
In this vignette, the combination of a recent high daily exposure, a 36-hour gap, tachycardia, tremor, sensory hypersensitivity, and muscle jerks warrants medical monitoring rather than a refill-only encounter. The 36-hour interval also falls within the alprazolam label’s reported 24–72-hour period when withdrawal seizures are greatest.
Recent withdrawal seizure, delirium, unstable vital signs, or an anticipated severe or complicated withdrawal course should prompt inpatient or otherwise medically managed care. Respiratory compromise should also prompt medical care, particularly when opioids, alcohol, or other sedatives may be involved. Psychiatric observation alone may be inadequate when the main risk is seizure, delirium, or medical instability.
If a generalized seizure occurs, manage it as a medical emergency: protect the airway and patient from injury, check bedside glucose, provide monitored care, and follow an appropriate acute seizure protocol; when withdrawal is suspected, a benzodiazepine is typically first-line. Do not use an antidepressant or antipsychotic alone as a substitute for withdrawal-directed seizure treatment. If agitation or psychosis persists after withdrawal is being treated, adjunctive medication requires attention to seizure threshold, respiratory status, QT effects, and the underlying cause.
3. Taper after stabilization—without false precision
The immediate goal is to suppress dangerous withdrawal and establish a predictable medication plan. A longer-acting benzodiazepine may be considered for tapering, but conversion from alprazolam is not automatic. Liver function, concurrent medications, age, sedation risk, and incomplete cross-tolerance matter; dose-equivalence tables are estimates rather than exact conversions.
Current multidisciplinary tapering guidance generally suggests initial reductions of about 5%–10% every 2–4 weeks, usually not exceeding 25% every 2 weeks, with slower reductions when symptoms intensify or the patient has used high doses for a prolonged period. Those figures are a framework for supervised outpatient tapering—not a discharge prescription for someone with acute withdrawal risk.
The taper should include one prescriber or coordinated prescribers, a written schedule, frequent reassessment, controlled dispensing when appropriate, and treatment for the underlying anxiety disorder. A routine one-month refill at the escalated alprazolam dose, without a monitored plan, is not a safety plan; neither is sending the patient home with no withdrawal-management plan after abrupt cessation.
4. Treat panic after the withdrawal problem is controlled
Once the patient is medically stable, revisit the original diagnosis. Confirm the baseline pattern of unexpected attacks, persistent concern, avoidance, functional impairment, mood symptoms, trauma-related symptoms, substance use, and medical contributors.
Cognitive behavioral therapy is a central treatment option. For ongoing pharmacotherapy, guideline-supported choices include antidepressants such as SSRIs or, when appropriate, SNRIs or tricyclic antidepressants. Start cautiously, increase gradually, explain that benefit is delayed, and warn that anxiety or activation may temporarily increase early in treatment. Chronic benzodiazepine rescue is a poor substitute for treating the panic disorder and may recreate the same dependence cycle.
Common traps for residents and board candidates
- Calling it “just panic” because the cardiac workup is negative. Normal initial tests do not neutralize a withdrawal history.
- Calling every dose escalation addiction. Separate tolerance, physical dependence, misuse, and benzodiazepine use disorder.
- Converting automatically to diazepam. Longer-acting substitution can be useful, but it depends on hepatic function, interactions, age, and patient response.
- Applying an outpatient taper schedule during acute instability. First establish medical safety; then individualize the pace.
- Treating withdrawal agitation as primary psychosis. Address the withdrawal syndrome and seizure risk first; if an antipsychotic is needed for persistent psychosis or dangerous agitation, use it only as an adjunct with medical monitoring.
- Assuming a negative routine toxicology result settles the medication history. The prescription record, dose pattern, and timing of the last dose are often more informative.
Practical takeaways
- Panic symptoms and benzodiazepine withdrawal can occur together.
- New tremor, insomnia, sensory hypersensitivity, myoclonus, delirium, or seizures after missed alprazolam doses should prompt withdrawal-risk assessment; delirium, seizures, unstable medical status, or unreliable monitoring increase the need for inpatient or medically managed care.
- Physical dependence is expected with regular exposure and is distinct from benzodiazepine use disorder.
- Treat acute withdrawal medically, then taper gradually with a patient-specific plan.
- Longer-term panic treatment should emphasize CBT and appropriate antidepressant therapy rather than repeated benzodiazepine rescue.
